The changes and clinical significance of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with chronic heart failure

Abstract

Objective To explore the plasma levels and clinical significance of osteoprotegerin(OPG)and receptor activator of nuclear factor kappa B ligand(RANKL)in patients with chronic heart failure(CHF).Methods In 110 patients with CHF and 80 normal controls,the plasma levels of OPG and RANKL were measured by enzyme-linked immunosorbentassay method.Results The plasma level of OPG in patients with CHF[(135.91±41.83)ng/L]was significantly higher than that in normal controls[(90.13±29.09)ng/L](P＜0.05).The plasma level of RANKL in patients with CHF[(90.82±32.14)ng/L]was significantly higher than that in normal controls[(59.78±20.11)ng/L](P＜0.05).The plasma levels of OPG and RANKL increased with the augment of NYHA functional ranking(P＜0.05).The plasma levels of OPG and RANKL had negative relationship with left ventricular ejection fraction(r=-0.33 and-0.36,P＜0.05).Conclusions The plasma levels of OPG and RANKL in patients with CHF are elevated and related with heart function.OPG and RANKL may participate in the occurrence and development of CHF. Key words: Heart failure; Osteoprotegerin; Systemic inflammatory response syndrome; Receptor activator of nuclear factor-kappa B ligand